Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC

被引：0
|
作者：
Piedra, A. [1 ,2 ]
Guinart-Cuadra, A. [2 ,3 ]
Mulet, M. [3 ]
Zamora, C. [3 ]
Alejandre, J. [3 ]
Martinez-Recio, S. [1 ,2 ]
Barba, A. [1 ,2 ]
Sullivan, I. [1 ]
Serra-Lopez, J. [1 ]
Isla, D. [4 ]
Arriola, E. [5 ]
Paz-Ares, L. [6 ]
Diz, M. P. [7 ]
Moreno, A. L. [8 ]
Callejo, A. [9 ]
Vidal, S. [3 ]
Majem, M. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Inst Recerca St Pau, Barcelona, Spain
[4] Hosp Univ Lozano Blesa, Zaragoza, Spain
[5] Hosp del Mar, Barcelona, Spain
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] Complejo Asistencial Univ Leon, Leon, Spain
[8] Hosp Univ Reina Sofia, Cordoba, Spain
[9] AstraZeneca Farmaceut Spain SA, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Small-cell lung cancer; Leukocyte-platelet complexes; PD-L1 expression on circulating cells;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.13C.03
引用
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
  • [31] PD-L1 expression in primary tumor and circulating tumor cells in patients with small cell lung carcinomas
    Ilie, Marius
    Hofman, Veronique
    Long, Elodie
    Butori, Catherine
    Lalvee, Salome
    Selva, Eric
    Venissac, Nicolas
    Mouroux, Jerome
    Marquette, Charles Hugo
    Hofman, Paul
    CANCER RESEARCH, 2016, 76
  • [32] Monitoring PD-L1 expression on circulating tumor cells (CTCs) in patients with NSCLC treated with PD1 inhibitors.
    Guibert, Nicolas Marie
    Delaunay, Myriam
    Lusque, Amellie
    Gouin, Sandrine
    Boubekeur, Nadia
    Rouquette, Isabelle
    Clermont, Estelle
    Fourtoul, Aurelien
    Favre, Gilles
    Pradines, Anne
    Mazieres, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [33] The expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer
    Wang, Wei
    Zhang, Tao
    FUTURE ONCOLOGY, 2021, 17 (13) : 1625 - 1635
  • [34] Isolation of circulating tumor cells and evaluation of PD-L1 expression in metastatic lung cancer
    Dhar, Manjima
    Che, James
    Wong, Jessica M.
    Pao, Edward
    Yu, Victor S. H.
    Matsumoto, Melissa
    Goldman, Jonathan
    Garon, Edward
    Sollier, Elodie
    Kulkarni, Rajan
    Di Carlo, Dino
    CANCER RESEARCH, 2015, 75
  • [35] Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
    Kallergi, Galatea
    Vetsika, Eleni-Kyriaki
    Aggouraki, Despoina
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Koinis, Filippos
    Katsarlinos, Panagiotis
    Trypaki, Maria
    Messaritakis, Ippokratis
    Stournaras, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [36] Dynamic change of PD-L1 expression on circulating tumor cells in advanced breast cancer undergoing PD-1 blockade therapy.
    Wang, Tao
    Zhou, Jinmei
    Zhang, Shaohua
    Bian, Li
    Hu, Zhiyuan
    Jiang, Zefei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.
    Moran, Jillian
    Adams, Daniel L.
    Bravo, Pablo Lopez
    He, Jianzhong
    Qiao, Yawei
    Xu, Ting
    Liao, Zhongxing X.
    Gardner, Kirby P.
    Tang, Cha-Mei
    Lin, Steven H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
    Zamora, Carlos
    Riudavets, Mariona
    Anguera, Georgia
    Alserawan, Leticia
    Sullivan, Ivana
    Barba, Andres
    Serra, Jorgina
    Ortiz, M. Angels
    Gallardo, Pablo
    Perea, Lidia
    Gavira, Javier
    Barnadas, Agusti
    Majem, Margarita
    Vidal, Silvia
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (06) : 1691 - 1704
  • [39] Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma
    Roderburg, Christoph
    Loosen, Sven H.
    Bednarsch, Jan
    Alizai, Patrick H.
    Roeth, Anjali A.
    Schmitz, Sophia M.
    Vucur, Mihael
    Luedde, Mark
    Paffenholz, Pia
    Tacke, Frank
    Trautwein, Christian
    Ulmer, Tom F.
    Neumann, Ulf Peter
    Luedde, Tom
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [40] Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Salvia, Roser
    Rico, Laura G.
    Moran, Teresa
    Bradford, Jolene A.
    Ward, Michael D.
    Drozdowskyj, Ana
    Climent-Marti, Joan
    Martinez-Caceres, Eva M.
    Rosell, Rafael
    Petriz, Jordi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
12345